Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVID Trial: Enoxaparin for Ambulatory COVID-19
NCT04400799Phase 3Terminated
- Sponsor
- University of Zurich
- Start
- Jun 2020
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of enoxaparin in coronavirus disease 2019 (COVID-19), sponsored by University of Zurich. Started Jun 2020; status: terminated.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04400799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400799.